DE NOVO MYELODYSPLASTIC SYNDROME
Clinical trials for DE NOVO MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new DE NOVO MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for DE NOVO MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to restore blood counts in bone marrow failure
Disease control Recruiting nowThis study tests a mix of drugs that calm the immune system and boost white blood cells in people with aplastic anemia or certain types of MDS. The goal is to improve low blood counts by targeting immune cells that may be attacking the bone marrow. About 140 adults will take part…
Matched conditions: DE NOVO MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo targets hard-to-treat leukemia in early trial
Disease control Recruiting nowThis study tests a mix of chemotherapy drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to see how well the treatment kills cancer cells and what side effects it causes. About 270 adults will …
Matched conditions: DE NOVO MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:52 UTC
-
New drug cocktail shows promise for tough blood cancers
Disease control Recruiting nowThis study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or a fast-growing form of chronic myeloid leukemia. The goal is to see how well these drugs ki…
Matched conditions: DE NOVO MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 24, 2026 16:20 UTC